Organigram Sees Canaccord Raise Price Target To $3.25 After Earnings

On January 11th, Organigram Holdings (TSX: OGI) issued its second fiscal quarter of 2022. The company reported net revenues of $30.38 million, or a 22.2% increase quarter over quarter. The company also reported a cost of sales of $27.92 million, meaning the company’s gross margin before fair value changes was $2.45 million. The company reported adjusted EBITDA of ($1.88) million, and a net loss of $1.3 million. Cash and equivalents dropped 8.5% to $168.04 million

Organigram currently has 13 analysts covering the stock with an average 12-month price target of C$3.26, or a 53% upside to the current stock price. Out of all 13 analysts, 2 have strong buy ratings, 3 have buys and the other 8 analysts have hold ratings. Cantor Fitzgerald currently holds the street high 12-month price target at C$5.30 or a 148% upside, while the lowest price target comes in at C$2.25.

In Canaccord’s earnings review, they raise their 12-month price target to C$3.25 from C$3.00 and upgrade Organigram to a speculative buy from a hold rating.

For the results, Organigram reported better than expected results compared to Canaccord’s revenue estimate. Canaccord expected revenues to be $28.64 million while they expected adjusted gross margins of $3.7 million, which were higher than the actual reported result.

Canaccord says that the revenue beat primarily comes from Organigram’s better-than-expected Canadian adult-use sales. Organigram’s ability to gain market share, going from 7% to 7.5% of the Canadian adult-use market, while other larger LP’s have seen material market share decline has surprised Canaccord.

Canaccord goes into some detail as to why the double upgrade, saying that the better-than-expected results bring momentum into their fiscal 2022. Though they say that the Canadian cannabis landscape continues to face a number of different headwinds, they believe the companies ability to execute over the last two quarters and “its ability to pivot its products to offer a wider array of in demand SKUs,” gives Canaccord hope for the company.

Below you can see Canaccord’s updated fiscal full-year 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

First Majestic Encounters 711 g/t Silver Equivalent Over 8.0 Metres In Ongoing Exploration At Los Gatos

Related News

Eldorado Gold: Analyst Ratings Unchanged Despite Production Beats

Eldorado Gold (TSX: ELD) released their Q2’20 preliminary results earlier this week, which included production...

Saturday, July 11, 2020, 08:30:00 AM

K92 Mining Sees Canaccord Lift Target To $12.50 After Strong Second Quarter

Earlier this week, K92 Mining Inc. (TSX: KNT) reported its second quarter financial results. The...

Friday, August 19, 2022, 04:44:00 PM

Cresco Labs: Analysts Raise Targets Following Massachusetts Acquisition

On March 18th, Cresco Labs (CSE: CL) announced the acquisition of Cultivate, a Massachusetts-based vertically...

Tuesday, March 23, 2021, 11:53:00 AM

Tilray: Canaccord Cuts Price Target To $12 After Q1 Results

On October 7, Tilray Inc (TSX: TLRY) reported their first quarter financial results for the...

Tuesday, October 12, 2021, 10:17:00 AM

Lundin Gold Sees $14 Price Target Reiterated By BMO

Lundin Gold Inc. (TSX: LUG) last week announced it’s third-quarter production results. The company said...

Monday, October 10, 2022, 03:15:00 PM